Genmab — April 2024
-
-
On 25 April 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Rybrevant. PAPILLON -amivantamab in combination with carboplatin and
pemetrexed for the first-line treatment https://www.ema.europa.eu/en/medicines/human/variation/rybrevant -
tisotumab vedotin submission in japan
https://genmab.co.jp/pressrelease/ -
AMGEN TO SUBMIT TEPROTUMUMAB MARKETING AUTHORIZATION APPLICATION TO THE EUROPEAN MEDICINES AGENCY https://www.amgen.com/newsroom/press-releases/2024/04/amgen-to-submit-teprotumumab-marketing-authorization-application-to-the-european-medicines-agency
-
In March 2024, Amgen submitted a marketing authorization application to the Medicines and Healthcare products Regulatory Agency (MHRA) in Great Britain, a New Drug Submission (NDS) to Health Canada and an application to the Therapeutic Goods Administration (TGA) in Australia for teprotumumab. Teprotumumab is also under review by the Ministry of Health, Labour and Welfare (MHLW) in Japan.
-
Godmorgen
-
Genmab-partner vil have Tepezza godkendt i EU
i dag kl. 08:04 ∙ MarketWireGenmabs amerikanske partner Amgen vil have øjenmidlet Tepezza godkendt til markedsføring i EU.
Det skriver Amgen i en pressemeddelelse ifølge Medwatch.
I pressemeddelelsen oplyses det, at Amgen har indsendt en markedsføringsansøgning for Tepezza til de europæiske myndigheder.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind